In a pivotal moment for BioMarin Pharmaceutical, the company posted strong Q4 2023 results, with Voxzogo sales significantly exceeding expectations and providing a solid foundation for ambitious 2024 guidance, even as activist investor Elliott Management acquires a substantial stake, hinting at potential strategic changes.
The world of biotech investing is rarely static, and BioMarin Pharmaceutical (BMRN), a company long focused on developing treatments for rare genetic disorders, is a prime example of this dynamism. Recent financial disclosures from Q4 2023, coupled with significant investor movements, paint a picture of a company at a strategic crossroads, balancing impressive product growth with increasing external scrutiny.
For long-term investors, understanding the nuances behind the headlines is crucial. This deep dive will unpack BioMarin’s latest performance, analyze the implications of activist investor involvement, and explore the potential trajectory for its key therapeutic assets.
A Strong Finish to 2023: The Voxzogo Effect
BioMarin delivered a compelling performance in the fourth quarter of 2023, surpassing analyst expectations on both its top and bottom lines. The company reported an adjusted earnings per share of 49 cents, comfortably beating the Zacks consensus estimate of 44 cents. This represented a substantial 48% year-over-year increase, primarily propelled by robust revenue growth that also managed to offset rising research and development expenses, as detailed in BioMarin’s official press release. Total revenues for the quarter climbed 20% year over year to $646.2 million, exceeding the Zacks consensus estimate of $636.7 million, according to BioMarin’s investor relations.
The undisputed star of the quarter was Voxzogo, the company’s approved treatment for achondroplasia. Sales of Voxzogo surged to $145.7 million, marking an impressive 118% increase year over year and an 18% jump quarter over quarter. This stellar performance was largely attributed to the successful U.S. label expansion to include younger age groups (under five years), which was secured in October of the prior year. The drug’s sales significantly surpassed both Zacks consensus estimates and internal model projections, underscoring its pivotal role in BioMarin’s growth story.
Beyond Voxzogo, other marketed brands also contributed positively:
- Vimizim sales rose 15% year over year to $175.6 million, also beating consensus estimates.
- Palynziq injection sales increased 21% year over year to $87.8 million, exceeding expectations.
- Brineura generated sales of $43.6 million, up 2% over the year-ago quarter.
- Aldurazyme revenues totaled $42.7 million, up 14%, likely due to favorable timing of order fulfillment to Sanofi‘s subsidiary, Genzyme, which is BioMarin’s sole customer for the drug.
However, not all products enjoyed growth. Naglazyme sales saw a slight decline of 2% to $98.3 million, and Kuvan revenues fell 32% to $36.7 million, continuing to face significant pressure from generic competition since losing U.S. market exclusivity in late 2020.
Roctavian’s Rocky Road: A Gene Therapy’s Early Challenges
One product that continues to draw significant investor attention, albeit for mixed reasons, is Roctavian, the first and only one-shot gene therapy approved for treating adults with severe hemophilia A in the United States and Europe. While initially hailed as a groundbreaking therapy, its sales performance has been slower than many investors anticipated. In Q4 2023, Roctavian generated $2.7 million in sales, an improvement from $0.7 million in the previous quarter, but still a modest contribution to the company’s overall revenue.
Historically, there was considerable excitement surrounding Roctavian’s path to market. In an earlier positive sign, the FDA announced it would not hold an advisory committee meeting to discuss the proposed therapy, effectively streamlining the review process and indicating confidence in the data. However, translating this regulatory success into significant commercial uptake has proven challenging in the gene therapy space, where patient identification, access, and reimbursement complexities are common hurdles.
Activist Investor Elliott Management Enters the Fray
Adding another layer of intrigue to BioMarin’s narrative is the emergence of activist investor Elliott Investment Management, which has reportedly built a sizable stake exceeding $1 billion in the company. As Reuters reported in late 2023, Elliott has been in discussions with BioMarin for months. While the exact nature of their demands remains undisclosed, Elliott’s history of successfully driving strategic changes in other healthcare companies suggests potential pressure for operational efficiencies, portfolio optimization, or even leadership adjustments.
This development comes on the heels of recent changes at the top, with Alexander Hardy succeeding long-time CEO Jean-Jacques Bienaimé as President and CEO effective December 1, 2023. Such leadership transitions often coincide with strategic re-evaluations, and Elliott’s presence could amplify calls for clear direction, particularly regarding assets like Roctavian and the broader pipeline.
Forward Look: 2024 Guidance and Pipeline Expansion
Looking ahead, BioMarin’s management has provided optimistic guidance for 2024, signaling continued growth. The company expects total revenues to range between $2.7 billion and $2.8 billion, implying an increase of approximately 14% year over year at the midpoint. This forecast aligns closely with the Zacks consensus estimate of around $2.79 billion. Adjusted earnings per share are projected to be in the range of $2.60 to $2.80, suggesting robust 30% growth over 2023 levels at the midpoint.
While Voxzogo is anticipated to be a primary revenue driver, management expects only a modest contribution from Roctavian sales in 2024, acknowledging the ongoing ramp-up challenges. Furthermore, BioMarin is actively investing in expanding the potential of Voxzogo:
- A pivotal registrational program for a new potential second indication, hypochondroplasia (a condition characterized by impaired bone growth), commenced in Q4 2023.
- Plans are underway to initiate two additional clinical programs later in 2024, evaluating Voxzogo in idiopathic short stature and genetic short stature conditions.
The company also announced a strategic portfolio review of all R&D programs, with a comprehensive update expected at its Investor’s Day event later this year. This review, potentially influenced by Elliott Management’s input, aims to determine which pipeline programs should be advanced for further development, underscoring a commitment to optimizing future growth drivers.
The Long-Term Investment Perspective
BioMarin Pharmaceutical finds itself in an intriguing position. Its core business, focusing on rare genetic disorders, continues to demonstrate strong product performance, particularly with Voxzogo. However, the commercial hurdles for novel gene therapies like Roctavian and the strategic influence of activist investors like Elliott Management introduce layers of complexity and potential catalysts for change.
For investors with a long-term horizon, BioMarin’s ability to sustain Voxzogo’s growth trajectory, effectively manage its pipeline (including the strategic review), and navigate the demands of its new activist shareholder will be critical. The company’s focus on high-unmet-need areas offers inherent value, but execution in a competitive and rapidly evolving biotech landscape will determine its ultimate success. The Zacks Rank currently places BioMarin as a #3 (Hold), suggesting a cautious but watchful approach as these strategic developments unfold.
